Navigation Links
Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
Date:2/2/2009

HAWTHORNE, N.Y., February 2, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS). The Company expects that the NDA filing, if accepted, will be subject to standard review, which would provide a target for the FDA to complete its review within ten months from receipt of the submission.

"This NDA filing is a major milestone for Acorda and our Fampridine-SR development program," said Acorda Therapeutics President and CEO Ron Cohen, M.D. "Walking impairment is one of the most pervasive and alarming aspects of MS for patients, their families and their health care providers. There are no medicines currently indicated to improve walking ability in people with MS, and Fampridine-SR therefore may represent an important new approach to MS therapy. We are excited to have taken this major step toward potentially making Fampridine-SR available to help people with MS."

Approximately 400,000-500,000 people in the Unites States have MS, and recent studies indicate that between 64-85% of people with MS have walking disability1,2. Fully 70% of people with MS who have walking disability report it to be the most challenging aspect of their disease1.

The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that involved 540 people with MS and were conducted under Special Protocol Assessments (SPAs) from the FDA. The safety and efficacy profile of Fampridine-SR was consistent across Phase 2 and Phase 3 trials. Overall, the NDA filing included more that 50 clinical studies of Fampridine-SR. The total exposure to Fampridine-SR in MS studies filed as part of the NDA was over 1,20
'/>"/>

Contact: Jeff MacDonald
jmacdonald@acorda.com
914-347-4300
Ruder Finn Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. A novel target for therapeutics against Staph infection
2. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
3. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. ORNL supercomputer simulation wins prize for fastest-running science application
10. Track your fitness, environmental impact with new cell phone applications
11. New filtering technology has environmental, industrial applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... After a decade and a half of near stagnation, ... chronic illness instead of a terminal disease, a leading Colorado ... drugs have different and innovative methods of action. One is ... another is radiotherapy; and the final one is the first ...
... ingredient in the food industry because of its association with ... the February issue of the Journal of Food Science ... fish oil can be added to goat cheese to deliver ... or shelf-life. Fish oil delivers higher levels and more ...
... Republic of Congo has formally expanded Nouabal-Ndoki National Park ... most pristine forests and a population of "nave" chimpanzees ... apes investigate the conservationists who study them rather than ... 100-plus square-mile dense swamp forest and its unique great ...
Cached Biology News:4 new drugs will change prostate cancer care 2Great news for chimpanzees 2Great news for chimpanzees 3
(Date:10/17/2014)... UT Arlington engineering professors have received a $451,781 Air ... material surface at the micro- and nano-scale level that ... Haiying Huang, professor of Mechanical and Aerospace Engineering, said ... more efficient than taking X-rays of an aircraft,s wing., ... early stages when we look at it on this ...
(Date:10/17/2014)... HILDEN, Germany , October 17, ... , Translational research in cancer and other diseases ... the American Society of Human Genetics annual meeting ... linked to Ingenuity ®  Knowledge Base greatly exceeds ... Ingenuity ®  Variant Analysis™ adds fully ...
(Date:10/17/2014)... Bioquell, provider of germ-eliminating robots ... facilities around the world to decontaminate locations where ... the many places the hydrogen peroxide vapor technology ... Dallas and at the National Institutes of Health ... been utilized to decontaminate patient rooms, equipment, and ...
(Date:10/17/2014)... global SWIR market report defines and segments the concerned ... market is valued at $60.1 million in 2014, and ... a CAGR of 10.2% from 2014 to 2019. , ... report, to get an idea of the in-depth analysis ... of the market, and is supported by various tables ...
Breaking Biology Technology:UT Arlington project to detect possible damages in aircraft parts early in process 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3
... Watersports enthusiasts will soon be able to surf in ... The National Physical Laboratory (NPL) and UK wetsuit manufacturer, ... sports market. It approached NPL, the UK,s measurement institute, ... warm, to improve its product design. In particular it ...
... CAMBRIDGE, Massachusetts , May ... SHPGY ), the global specialty biopharmaceutical,company, today announced that ... from NORD. Shire was recognized for its efforts to ... enzyme replacement,therapy (ERT) for the treatment of Type 1 ...
... ATLANTA , May 19 Hothead ... to adapt the Sivix key computing fob and associated ... safety solutions.  These solutions are based upon the H.O.T.™ ... unit inside the helmet of an athlete, firefighter, soldier, ...
Cached Biology Technology:A warmer future for watersports 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 3Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 4Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 5Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
...
... Marker consists of ten double-stranded RNAs, 10, ... 500 and 1,000 base pairs. The dsRNA ... determinating sizes of double-stranded RNAs. A twenty ... Marker is adjusted to approximately 25 ng/µl ...
... These protein size markers are a mixture ... 16 to 100 kDa. The markers provide ... gels after staining with Coomassie blue. Because ... II sequence, the markers can also be ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Biology Products: